Key Highlights

Risk & Performance

Based on historical performance

High Risk

Score: 80/100

Failure Rate

40.0%

2 terminated/withdrawn out of 5 trials

Success Rate

60.0%

-26.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

100%

3 of 3 completed trials have results

Key Signals

3 with results

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Loading network data...

Showing 5 of 5 trials

Autologous Fecal Microbiota Transplantation to Prevent Antibiotic Resistant Bacteria Colonization

Role: lead

Safety of FMT: OpenBiome Outcomes and Longitudinal Follow-up (STOOL) for Recurrent Clostridium Difficile Infection

Role: lead

Transfer of Healthy Gut Flora for Restoration of Intestinal Microbiota Via Enema for Patients in the Rehabilitative Phase of Malnutrition

Role: lead

Fecal Microbial Transplant (FMT) for Sjogrens Syndrome

Role: collaborator

A Trial of Encapsulated Fecal Microbiota for Vancomycin Resistant Enterococcus Decolonization

Role: lead

All 5 trials loaded